NeuroSense Therapeutics Ltd. Research and Development Expense
NeuroSense Therapeutics Ltd. (NRSN) reported Research and Development Expense of $6.23 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-03-31
| Period end | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|
| 2025-12-31 | $6.23M 20-F · filed 2026-03-31 | ||
| 2025-06-30 | $2.50M 6-K · filed 2025-08-01 | ||
| 2024-12-31 | $5.70M 20-F · filed 2026-03-31 | ||
| 2024-06-30 | $3.73M 6-K · filed 2025-08-01 | $3.45M 6-K · filed 2024-09-30 | |
| 2023-12-31 | $7.27M 20-F · filed 2026-03-31 | ||
| 2023-06-30 | $3.81M 6-K · filed 2024-09-30 | ||
| 2022-12-31 | $5.59M 20-F · filed 2025-04-07 | ||
| 2021-12-31 | $1.39M 6-K · filed 2024-06-17 |